Ticker

CREO.LSE

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; SlypSeal Flex, an electrosurgical haemostasis device; and SpydrBlade Flex, a bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the gastrointestinal (GI) tract; ScopeClip for clip placement in the digestive tract; ScopeInject for endoscopic injection into GI mucosa; ScoprGrasp, a disposable grasping forceps for digestive and bronchial endoscopy; ScopeBite, a portfolio of digestive biopsy forceps; and other products for gastroenterology, pulmonology, and urology. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.